GlassScriptPhysician profile
Abhishek Mishra
NPI 1053816587
$1,009.74
in general payments reported to CMS, 2019-2025
15 companies · $122 in 2025
The $122 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $134 · 2023: $356 · 2024: $397 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $236.20 | 2023-2024 | Renasys Go V2 Home, Collagenase Santyl |
| Neurocrine Biosciences, INC. | $148.48 | 2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $121.85 | 2025 | Cobenfy |
| Bayer Healthcare Pharmaceuticals INC. | $101.38 | 2023 | |
| Amgen INC. | $99.61 | 2022-2024 | Repatha |
| Mylan Specialty L.P. | $74.55 | 2022 | |
| Sumitomo Pharma America, INC. | $61.04 | 2023 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $47.30 | 2023 | Nuedexta |
| Aroa Biosurgery Incorporated | $28.73 | 2024 | |
| Avanir Pharmaceuticals, INC. | $21.11 | 2022 | |
| Next Science LLC | $21.08 | 2023 | Blastx, Xperience, Surgx |
| Teva Pharmaceuticals USA, INC. | $15.41 | 2023 | Austedo Xr |
| Lilly USA, LLC | $13.28 | 2022 | |
| Urovant Sciences INC | $12.08 | 2022 | |
| Kerecis Limited | $7.64 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhishek Mishra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.